In brief
- The VA (U.S. Department of Veterans Affairs) announced PIVOT, whose registry targets a sample of 240 veterans with treatment-resistant depression across five hospitals nationwide.
- There is no inert-placebo group: all participants receive psilocybin, with only the initial dose varying between groups.
- The registry identifies COMP360 as a product name; the study aims to evaluate outcomes, not establish approval or efficacy for all veterans.
PIVOT’s registry records 3 August 2026 as its actual start; the U.S. Department of Veterans Affairs (VA) announced on 5 August a phase 3 clinical trial evaluating psilocybin for veterans with treatment-resistant major depression, with or without associated post-traumatic stress disorder. The study, sponsored by the VA’s own Office of Research and Development, joins a wave of institutional trials that have placed psilocybin on the radar of the American public health system in recent months.
An active-dose comparator
The inspected registry targets 240 veterans between the ages of 18 and 75 at five VA medical centers: Birmingham and Tuscaloosa (Alabama), Portland (Oregon), Philadelphia (Corporal Michael J. Crescenz VA Medical Center), and Seattle (VA Puget Sound). To qualify for the study, participants must have a major depressive episode with a score of at least 20 on the MADRS (Montgomery-Åsberg) scale and must have unsuccessfully tried two or more conventional antidepressants.
The unique aspect of the design is the absence of an inert placebo arm. Both groups receive COMP360, the pharmaceutical-grade synthetic psilocybin developed by Compass Pathways, in two dosing sessions spaced one month apart, always accompanied by psychological support. What varies between groups is the dose administered in the first session; in the second session, all participants receive the same amount. The outcome table lists MADRS with a two-week timeframe; other sections describe assessments after both sessions and a milestone four weeks after randomization. This evidence does not unambiguously anchor that timeframe to the second session. Described follow-up reaches six months.
Institutional context
The launch of the trial comes months after President Trump signed an executive order in April 2026 regarding the “acceleration of medical treatments for serious mental illnesses,” which, among other things, seeks to streamline participation in clinical trials involving psychedelic substances. VA Secretary Doug Collins stated in the agency’s press release that “too many veterans live with mental health conditions that do not respond to available treatments,” as justification for opening this avenue of research within the public health system. According to the trial registry (NCT07226232), the primary completion is expected in December 2030, with the full study closing in June 2031—estimated dates that do not guarantee completion or prove rigor by themselves.
What this implies
The registry captured on 20 October shows RECRUITING, with its last posted update on 14 August; this does not directly verify places or enrollments at each centre today. It contains no outcomes comparing efficacy or safety between doses. Exact amounts are not specified in its arms, and it cannot establish that every participant experiences subjective effects or that blinding succeeded. The clinical research within institutions should be assessed through design, outcomes and transparency, without treating announcements or funding as proven efficacy.
Source
- U.S. Department of Veterans Affairs. VA launches psilocybin trial for Veterans with treatment-resistant depression. VA News, August 5, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
